Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,282.50p - 1,823.50p
Previous CloseN/A
Volume367.08K
Average Volume (3M)8.22M
Market Cap
£59.06B
Enterprise Value68.32B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)22.9
Beta0.62
Next Earnings
Apr 30, 2025EPS Estimate
41.3Last Dividend Ex-Date
Feb 20, 2025Dividend Yield4.21%
Share Statistics
EPS (TTM)0.63
Shares Outstanding4,145,945,300
10 Day Avg. Volume6,808,480
30 Day Avg. Volume8,223,473
Standard Deviation0.07
R-Squared0.14
Alpha-0.00388
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.91
Price to Cash Flow (P/CF)14.50
P/FCF Ratio22.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
1,580.42pPrice Target Upside10.60% Upside
Rating ConsensusHold
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
EarningsAn unexpected £2bn SBB programme added to the projected core EPS, while the 2031 long-term outlook was also uplifted.
Litigation And PipelineWith the Zantac litigation almost fully settled, vaccines slowdown baked into the numbers and interesting triggers on the agenda, including approvals of MenABCWY, Nucala COPD, Gepo, Depe and Blenrep, all in 2025.
Bears Say
Competitive ThreatGilead's 6-monthly sub-cutaneous lenacapavir, expected to launch soon, has already led to a reduction in sales projections for GSK's Apretude.
Research And DevelopmentStarting three major, expensive COPD PIII programs is likely to put material upward pressure on R&D spend and margin compression just as revenues decline on HIV loss of exclusivity.
Vaccines BusinessThe outlook for GSK's vaccine division is concerning, with expectations of a decline, especially with challenges in the Chinese market.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.08% Insiders
11.03% Mutual Funds
0.08% Other Institutional Investors
76.77% Public Companies and Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1282.50p and its highest was 1823.50p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £59.06B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Apr 30, 2025 which is in 66 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Feb 05, 2025. The company reported 0.232p earnings per share for the quarter, beating the consensus estimate of 0.198p by 0.034p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of 15.999p which represents an annual dividend yield of 4.21%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 41.3.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,145,945,300 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.232p in its last earnings report, beating expectations of 0.198p. Following the earnings report the stock price went up 7.609%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
1,580.42p (10.60% Upside)
1,580.42p (10.60% Upside)
Insider Transactions
Sold Shares
Worth £10.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.58%
12-Months-Change
Fundamentals
Return on Equity
19.06%
Trailing 12-Months
Asset Growth
0.78%
Trailing 12-Months
Company Description
GlaxoSmithKline
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
---
GSK Stock 12 Month Forecast
Average Price Target
1,580.42p
▲(10.60% Upside)
Technical Analysis
Best Analysts Covering GSK
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
-0.10%
reiterated a sell rating 18 days ago
Copying Graham Parry's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of -0.10% per trade.
---